Executive Summary

The medical technology (medtech) sector is undergoing a profound transformation, with global forces reshaping market dynamics, care delivery, and competitive advantage. For Europe, these changes present both challenges and opportunities. The rise of volume-based procurement in China, the shift to outpatient settings, supply chain pressures, the impact of GLP-1 therapies, and the emergence of platform-based competition are not isolated trends – they are interconnected forces that will redefine how European medtech companies operate and compete. This analysis explores these trends through a European lens, assessing their implications for industrial strategy, innovation policy, cross-border investment, and the EU's broader economic resilience. Europe must respond proactively, leveraging its single market, research excellence, and manufacturing strengths to maintain leadership in a rapidly evolving global industry.

Introduction

Europe has long been a powerhouse in medical technology, home to world-leading firms, innovative startups, and robust research institutions. The sector contributes significantly to the EU economy, with a strong export base and high-value employment. However, the global medtech landscape is entering a period of accelerated change, driven by policy shifts, technological advances, and evolving healthcare models. Understanding these trends is critical for business leaders, investors, and policymakers seeking to navigate the next phase of growth.

This article draws on industry intelligence, including insights from Clarivate's Medtech Trends to Watch 2026, to examine five key trends and their strategic significance for Europe. Each trend is analyzed in terms of its impact on the European market, corporate strategy, industrial competitiveness, and the policy environment.

Main Analysis

1. China's Volume-Based Procurement: A Global Price-Setting Force

China's national volume-based procurement (VBP) program has evolved into a powerful market-structuring tool. The latest rounds have introduced more sophisticated anchor-pricing mechanisms, deeper price compression, and allocation systems favoring domestic manufacturers. While initially aimed at expanding patient access, VBP now exerts downward pressure on device prices, influencing pricing expectations and competitive positioning well beyond China.

For European medtech companies, this trend has dual implications. On one hand, China represents a significant market with growth potential, but VBP compresses margins and challenges traditional portfolio strategies. On the other, the pricing benchmarks set by China are increasingly referenced in other emerging markets and even in European tenders, creating a ripple effect. European firms must therefore reassess their pricing models, cost structures, and value propositions to remain competitive both in China and globally.

2. Outpatient and Ambulatory Settings: The New Frontier of Care

The migration of procedures from hospitals to outpatient settings is accelerating, particularly in the United States, where CMS policies are expanding the list of procedures covered in ambulatory surgical centers (ASCs). This trend is not confined to the U.S.; European healthcare systems are also witnessing a shift toward day surgery and outpatient care, driven by cost containment, patient preference, and technology advances.

For medtech manufacturers, this signifies a need to adapt product design, commercial models, and economic value propositions. Devices must be easier to use, more portable, and suited to lower-acuity settings. In Europe, where public health systems often dictate care pathways, this trend could influence procurement decisions and stimulate innovation in minimally invasive and connected devices. Companies that anticipate these shifts and invest in tailored solutions will gain a competitive edge.

3. Supply Chain Resilience: A Strategic Imperative

Global trade tensions, geopolitical uncertainty, and material cost fluctuations have exposed vulnerabilities in supply chains that were previously optimized for cost efficiency. Medtech companies now recognize supply chain resilience as a core element of business strategy. In Europe, where dependence on imported components and materials is significant, this trend is particularly acute.

European manufacturers are diversifying sourcing, re-evaluating manufacturing footprints, and investing in automation to buffer against volatility. There is also growing political support for nearshoring and strategic autonomy, with EU initiatives aiming to strengthen critical supply chains. For the medtech sector, this could mean new opportunities for domestic suppliers and increased investment in digital supply chain technologies. However, it also implies higher costs, which must be balanced against price pressures from global procurement.

4. GLP-1 Therapies: Reshaping Care Pathways

The rapid adoption of glucagon-like peptide-1 (GLP-1) receptor agonists for weight management and related conditions is having a profound effect on patient behavior and healthcare utilization. While bariatric surgery remains the most effective intervention for severe obesity, GLP-1s are changing referral patterns and influencing demand across adjacent device categories, including diabetes care, sleep apnea, and cardiovascular monitoring.

In Europe, where obesity rates are rising, the GLP-1 phenomenon is prompting healthcare systems to reconsider treatment algorithms and prioritize early intervention. For medtech companies, this creates both risks and opportunities. Device portfolios may need to be rebalanced as certain procedures see volume pressure, while new segments emerge for monitoring and supportive devices. The cross-sector impact of GLP-1s is a key consideration for strategic planning and investment decisions.

5. Platform-Based Competition: The Rise of Integrated Ecosystems

Enabling technologies, including robotics, imaging, navigation, and digital workflows, are transforming medtech from standalone products to integrated platforms. These platforms anchor entire service lines, support clinical decision-making, and enable data-driven care. Companies are investing heavily in ecosystem architectures that strengthen customer relationships and unlock new value propositions.

For Europe, platform innovation aligns with the EU's digital agenda and its ambition to lead in health data and artificial intelligence. However, the region faces challenges in scaling platforms due to fragmented healthcare markets and regulatory complexity. To compete globally, European companies must foster collaboration across borders, leverage the single market's scale, and invest in interoperable systems. Public-private partnerships and EU research funding will play a critical role in nurturing platform ecosystems.

Business Impact

The trends outlined above will have significant implications for Europe's medtech industry:

• Corporate Strategy: Companies will need to adopt more agile and adaptive business models, diversifying revenue streams and investing in digital capabilities. Portfolio rebalancing and strategic partnerships will become essential.
• Industrial Development: Supply chain resilience and nearshoring offer opportunities for European manufacturing, potentially reviving industrial activity in key regions. Advanced manufacturing and automation will drive productivity gains.
• Foreign Direct Investment (FDI): The need for local manufacturing and innovation hubs may attract FDI into Europe, particularly in digital health and platform technologies. Countries with attractive innovation ecosystems will compete for investment.
• Employment: While automation may mitigate some job losses in traditional manufacturing, new roles will emerge in software, data analytics, and service delivery. Reskilling and upskilling will be critical to harness the transition.
• Innovation: Platform-based competition and the shift to outpatient care create opportunities for disruptive startups and established firms to introduce differentiated solutions. Europe's strong research base can be leveraged to drive breakthrough innovations.
• Capital Markets: Investor interest in medtech is likely to remain strong, particularly for companies demonstrating resilience and growth potential in the face of pricing pressure. ESG considerations will influence investment decisions, given the sector's impact on healthcare outcomes.

European Perspective

The EU's response to these trends is shaped by its unique political and economic structures. The European Commission has prioritized strategic autonomy, industrial policy, and the digital transition, which are directly relevant to medtech. Initiatives like the European Health Data Space and the Digital Innovation Hubs can support the adoption of platform technologies. Meanwhile, the Green Deal's emphasis on sustainability is driving investments in eco-friendly manufacturing and circular economy principles.

Different member states face distinct challenges. Germany, France, and the Nordics have strong medtech sectors but must adapt to pricing pressures and global competition. Southern Europe, including Italy and Spain, offers potential for growth in outpatient care and digital health. Central and Eastern Europe are emerging as attractive manufacturing and R&D locations, benefiting from labor incentives and regional cooperation. Cross-border collaboration within the EU single market is essential to scale innovations and compete with larger players from the U.S. and Asia.

Future Outlook

Over the next 3–5 years, Europe's medtech landscape will evolve considerably. We expect to see:

• Consolidation and Partnerships: Companies will seek scale through mergers, acquisitions, and alliances, particularly in platform technologies and digital health. Cross-border deals within the EU will increase, supported by harmonized regulations.
• Regulatory Evolution: The implementation of the EU Medical Device Regulation (MDR) will mature, but further reforms may be needed to accommodate digital health and software-as-a-medical-device. A risk-based approach and accelerated pathways for innovation will be crucial.
• Focus on Value-Based Healthcare: Payers will increasingly demand evidence of clinical and economic value. Medtech firms will need to demonstrate improved outcomes and cost-effectiveness, driving development of real-world evidence capabilities.
• Reshoring and Manufacturing Transformation: Supply chain security will drive investments in automated, flexible manufacturing closer to major markets. Europe can become a leader in advanced medtech manufacturing, incorporating AI and robotics to reduce costs.
• Digital Integration: The convergence of medtech with AI and data analytics will accelerate, leading to more personalized and preventive care. Europe's health data infrastructure will be a competitive asset.
• Global Competition: China's push for self-sufficiency and the U.S. focus on innovation will intensify competition. Europe's ability to navigate pricing pressures while fostering innovation will determine its global position.

Conclusion

The medtech trends of 2026 are not merely passing phenomena; they signal a structural transformation of the industry. Europe must respond proactively by embracing innovation, fostering collaboration, and aligning policies with the evolving market reality. By leveraging its strengths in research, engineering, and social healthcare systems, Europe can turn these challenges into opportunities for sustainable growth, improved patient outcomes, and enhanced industrial competitiveness. The future of medtech in Europe will be defined by its capacity to adapt, innovate, and cooperate across borders.